Saxenda

Saxenda

liraglutide

Manufacturer:

Novo Nordisk

Distributor:

Novo Nordisk
Concise Prescribing Info
Contents
Liraglutide
Indications/Uses
Adjunct to a reduced-calorie diet & increased physical activity for wt management in adult w/ an initial BMI of ≥30 kg/m2 (obese) or ≥27 kg/m2 to <30 kg/m2 (overwt) in the presence of at least 1 wt related comorbidity eg, dysglycaemia (pre-diabetes or type 2 DM), HTN, dyslipidaemia or obstructive sleep apnoea.
Dosage/Direction for Use
SC Initially, 0.6 mg once daily. Increase to 3 mg once daily in increments of 0.6 mg w/ at least 1 wk interval to improve GI tolerability. Maintenance dose: 3 mg.
Administration
May be taken with or without food.
Contraindications
Special Precautions
Not to be administered as IV/IM. Not to be used a substitute for insulin. Not recommended in patients w/ CHF NYHA class IV; treatment w/ other products for wt management; obesity secondary to endocrinological or eating disorders or treatment w/ medicinal products that may cause wt gain; inflammatory bowel disease & diabetic gastroparesis. Increase risk of developing acute pancreatitis; cholelithiasis. Patients w/ thyroid disease. Monitor heart rate. Risk of dehydration & fluid depletion. Increased risk of hypoglycemia in combination w/ sulfonylurea. Severe renal impairment (CrCl <30 mL/min) & end-stage renal disease; severe hepatic impairment. Pregnancy & lactation. Elderly ≥75 yr. Childn & adolescent <18 yr.
Adverse Reactions
Nausea, vomiting, diarrhea, constipation. Hypoglycemia; insomnia; dizziness, dysgeusia; dry mouth, dyspepsia, gastritis, GERD, upper abdominal pain, flatulence, eructation, abdominal distension; cholelithiasis; inj site reactions, asthenia, fatigue; increased lipase/amylase.
Drug Interactions
Monitor INR of patients on warfarin & other coumarin derivatives. Decreased Cmax & delayed tmax of paracetamol (acetaminophen), atorvastatin, OCs. Increased Cmax of griseofulvin. Reduced AUC, decreased Cmax & delayed tmax of digoxin & lisinopril.
MIMS Class
Anti-Obesity Agents / Antidiabetic Agents
ATC Classification
A10BJ02 - liraglutide ; Belongs to the class of glucagon-like peptide-1 (GLP-1) analogues. Used in the treatment of diabetes.
Presentation/Packing
Form
Saxenda soln for inj 6 mg/mL
Packing/Price
(type 1 glass cartridge w/ bromobutyl plunger & stopper) 3 mL x 3 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in